C. Gnerre

发表

Physiologically-Based Pharmacokinetic Modeling of Macitentan: Prediction of Drug–Drug Interactions

R. de Kanter, A. Treiber, P. Sidharta, 2016, Clinical Pharmacokinetics.

Selexipag Active Metabolite ACT-333679 Displays Strong Anticontractile and Antiremodeling Effects but Low β-Arrestin Recruitment and Desensitization Potential

M. Iglarz, M. Clozel, C. Gnerre, 2017, The Journal of Pharmacology and Experimental Therapeutics.

Absorption, Metabolism, and Excretion of ACT-1004-1239, a First-In-Class CXCR7 Antagonist: In Vitro, Preclinical, and Clinical Data

H. E. Meyer zu Schwabedissen, J. Dingemanse, P. Sidharta, 2022, Frontiers in Pharmacology.

Lipophilicity Plays a Major Role in Modulating the Inhibition of Monoamine Oxidase B by 7‐Substituted Coumarins

B. Testa, P. Jenner, M. Catto, 2006, Chemistry & biodiversity.

Bosentan, a dual endothelin receptor antagonist, activates the pregnane X nuclear receptor.

U. Meyer, A. Treiber, J. Dingemanse, 2002, European journal of pharmacology.

LXR deficiency and cholesterol feeding affect the expression and phenobarbital-mediated induction of cytochromes P450 in mouse liver Published, JLR Papers in Press, June 1, 2005. DOI 10.1194/jlr.M400453-JLR200

J. Gustafsson, C. Handschin, U. Meyer, 2005, Journal of Lipid Research.

Interaction of psychotropic drugs with monoamine oxidase in rat brain

P. Carrupt, B. Testa, M. Kosel, 2001, The Journal of pharmacy and pharmacology.

The endothelin receptor antagonist macitentan for the treatment of pulmonary arterial hypertension: A cross‐species comparison of its cytochrome P450 induction pattern

A. Treiber, S. Delahaye, C. Gnerre, 2020, Pharmacology research & perspectives.

The metabolism and drug–drug interaction potential of the selective prostacyclin receptor agonist selexipag

R. de Kanter, A. Treiber, S. Delahaye, 2018, Xenobiotica; the fate of foreign compounds in biological systems.

Evolution of novel tricyclic CRTh2 receptor antagonists from a (E)-2-cyano-3-(1H-indol-3-yl)acrylamide scaffold.

D. Renneberg, H. Fretz, X. Leroy, 2013, Bioorganic & medicinal chemistry letters.

Novel 2-(2-(benzylthio)-1H-benzo[d]imidazol-1-yl)acetic acids: discovery and hit-to-lead evolution of a selective CRTh2 receptor antagonist chemotype.

H. Fretz, X. Leroy, M. Riederer, 2012, Bioorganic & medicinal chemistry letters.

Natural and synthetic geiparvarins are strong and selective MAO-B inhibitors. Synthesis and SAR studies.

P. Carrupt, B. Testa, B. Cosimelli, 2002, Bioorganic & medicinal chemistry letters.

Optimization of LpxC inhibitor lead compounds focusing on efficacy and formulation for high dose intravenous administration.

D. Ritz, R. Lange, S. Diethelm, 2019, Journal of medicinal chemistry.

Inhibition of monoamine oxidases by functionalized coumarin derivatives: biological activities, QSARs, and 3D-QSARs.

B Testa, P. Carrupt, B. Testa, 2000, Journal of medicinal chemistry.

4-((R)-2-{[6-((S)-3-Methoxypyrrolidin-1-yl)-2-phenylpyrimidine-4-carbonyl]amino}-3-phosphonopropionyl)piperazine-1-carboxylic Acid Butyl Ester (ACT-246475) and Its Prodrug (ACT-281959), a Novel P2Y12 Receptor Antagonist with a Wider Therapeutic Window in the Rat Than Clopidogrel.

D. Renneberg, M. Riederer, E. Meyer, 2015, Journal of medicinal chemistry.

Monoamine oxidase inhibitory activity of some Hypericum species native to South Brazil

B. Testa, C. Gnerre, A. Ferraz, 2001, The Journal of pharmacy and pharmacology.

Botanical (morphological, micrographic), chemical and pharmacological characteristics of Pfaffia species (Amaranthaceae) native to South Brazil

B. Testa, C. Barardi, G. Gosmann, 2003 .

Cross-species comparison of the metabolism and excretion of selexipag

A. Treiber, C. Gnerre, J. Segrestaa, 2019, Xenobiotica; the fate of foreign compounds in biological systems.

In vitro biotransformation of the selective serotonin reuptake inhibitor citalopram, its enantiomers and demethylated metabolites by monoamine oxidase in rat and human brain preparations

C. Bouras, B. Testa, B. Rochat, 2002, Molecular Psychiatry.

Regulation of CYP3A4 by the bile acid receptor FXR: evidence for functional binding sites in the CYP3A4 gene.

U. Meyer, R. Looser, C. Gnerre, 2004, Pharmacogenetics.

The evolution of drug-activated nuclear receptors: one ancestral gene diverged into two xenosensor genes in mammals

C. Handschin, U. Meyer, M. Podvinec, 2004, Nuclear receptor.

Discovery of the Potent, Selective, Orally Available CXCR7 Antagonist ACT-1004-1239.

F. Lehembre, C. Gnerre, S. Richard-Bildstein, 2020, Journal of medicinal chemistry.

Transcriptional Activation of Cytochrome P450 CYP2C45 by Drugs Is Mediated by the Chicken Xenobiotic Receptor (CXR) Interacting with a Phenobarbital Response Enhancer Unit*

J. Stegeman, U. Meyer, C. Gnerre, 2002, The Journal of Biological Chemistry.

Natural and Synthetic Xanthones as Monoamine Oxidase Inhibitors: Biological Assay and 3D‐QSAR

P. Carrupt, E. Fernandes, B. Testa, 2001 .

Identification of 2-(2-(1-naphthoyl)-8-fluoro-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)acetic acid (setipiprant/ACT-129968), a potent, selective, and orally bioavailable chemoattractant receptor-homologous molecule expressed on Th2 cells (CRTH2) antagonist.

H. Fretz, X. Leroy, M. Riederer, 2013, Journal of medicinal chemistry.

Discovery of Novel Inhibitors of LpxC Displaying Potent In Vitro Activity against Gram-Negative Bacteria.

D. Ritz, M. Wicki, A. Mac Sweeney, 2019, Journal of medicinal chemistry.

Regulation of human liver δ‐aminolevulinic acid synthase by bile acids

M. Zavolan, A. Peyer, U. Meyer, 2007 .

Species-specific mechanisms for cholesterol 7alpha-hydroxylase (CYP7A1) regulation by drugs and bile acids.

C. Martinez-Jimenez, C. Handschin, U. Meyer, 2005, Archives of biochemistry and biophysics.

Pharmacokinetic interactions between simvastatin and setipiprant, a CRTH2 antagonist

A. Halabi, A. Treiber, J. Dingemanse, 2014, European Journal of Clinical Pharmacology.

Monoamine oxidase inhibitory properties of some benzazoles: Structure-; Activity relationships

P. Carrupt, B. Testa, P. Crivori, 1999, AAPS PharmSci.

Regulation of human liver delta-aminolevulinic acid synthase by bile acids.

M. Zavolan, A. Peyer, U. Meyer, 2007, Hepatology.

Discovery of the Clinical Candidate IDOR-1117-2520: A Potent and Selective Antagonist of CCR6 for Autoimmune Diseases.

C. Gnerre, S. Richard-Bildstein, M. Murphy, 2024, Journal of medicinal chemistry.